Episode Details

Back to Episodes
A Glaucoma Laser Treatment Lowered Eye Pressure for 4 Years Without Cutting Into the Eye

A Glaucoma Laser Treatment Lowered Eye Pressure for 4 Years Without Cutting Into the Eye

Published 1 month, 3 weeks ago
Description

This audio article is from VisualFieldTest.com.

Read the full article here: https://visualfieldtest.com/en/a-glaucoma-laser-treatment-lowered-eye-pressure-for-4-years-without-cutting-into-the-eye

Test your visual field online: https://visualfieldtest.com

Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support

Excerpt:

A Glaucoma Laser Treatment Lowered Eye Pressure for 4 Years Without Cutting Into the Eye Evidence review current to September 21, 2026 Bottom line The newest 48-month results for femtosecond laser image-guided high-precision trabeculotomy, called FLigHT, are encouraging but still preliminary. In the original first-in-human cohort: 18 eyes from 12 patients were treated. 15 eyes remained evaluable at 48 months. Mean medicated intraocular pressure decreased from 21.4 ± 4.6 millimeters of mercury to 14.9 ± 2.6 millimeters of mercury. That is approximately a 27% reduction, or about 6.5 millimeters of mercury. Mean glaucoma medication use decreased only modestly, from 2.1 to 1.8 medications, and the reduction was not statistically significant. The study did not use medication washout. The treated channels reportedly remained visible and patent on gonioscopy and anterior-segment optical coherence tomography after four years. No serious FLigHT-related adverse events were reported in the available 48-month reports. The key qualification is that this was a small, single-center, nonrandomized, single-arm study without a control group. The 48-month data have been presented at the European Society of Cataract and Refractive Surgeons meeting, but a complete peer-reviewed 48-month publication was not available in the public sources reviewed. My assessment is: > FLigHT has shown a credible four-year durability signal and pressure lowering in the general range of trabecular minimally invasive glaucoma surgery. It has not yet demonstrated that it is better than selective laser trabeculoplasty, equivalent to established minimally invasive glaucoma surgery, or reliably medication-sparing. The most likely future role is not replacing every glaucoma procedure. It is becoming a treatment option between selective laser trabeculoplasty and incisional minimally invasive glaucoma surgery, particularly for patients with open-angle glaucoma who need pressures in the low-to-mid teens but do not yet require the very low pressures often sought with trabeculectomy. --- What was newly reported at the 2026 European Society of Cataract and Refractive Surgeons meeting? The 44th European Society of Cataract and Refractive Surgeons Congress was held in London from September 11 through September 15, 2026. The 48-month FLigHT update was presented by Zoltan Nagy and colleagues as ePoster POGAU064. Ophthalmology Times conference report Media MICE conference report () The 48-month results For the full table, please open this article on visualfieldtest.com. The pressure reduction was statistically significant, with a reported P value below .001. However, the available conference reports do not provide the full patient-level dataset, confidence intervals, individual pressure trajectories, or a complete breakdown of medication classes. How many patients were still being followed? The publicly described 48-month result is based on 15 of the original 18 treated eyes, which represents an eye-level retention of approximately 83%. The accessible reports do not clearly identify: How many individual patients those 15 eyes represented The exact reason each missing eye was not included Whether missing eyes were lost to follow-up, had incomplete testing, or were excluded for another reason Therefore, the most defensible statement is:

Listen Now

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us